Examination of hemodynamics of liver tumors such as hepatocellular carcinoma and hepatic parenchyma using intra-arterial contrast-enhanced ultrasonography
Not Applicable
Recruiting
- Conditions
- hepatocellular carcinoma, liver cirrhosisD006528
- Registration Number
- JPRN-jRCT1030210558
- Lead Sponsor
- Shiozawa Kazue
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Based on the Evidence-based Clinical Practice Guidelines for hepatocellular carcinoma developed by the
Japan Society of Hepatology, the cases in which transarterial chemoembolization or hepatic arterial infusion
chemotherapy for hepatocellular carcinoma were selected and consent was obtained for this study.
Exclusion Criteria
Based on the same guidelines, the cases that are not indicated for transarterial chemoembolization or hepatic arterial infusion chemotherapy for hepatocellular carcinoma and for which consent cannot be obtained for this study.
Excludes minors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Recurrence rate and survival time after transarterial chemoembolization for hepatocellular carcinoma.<br>2. Adverse events<br>Transarterial chemoembolization: a. Fever, b. Abdominal pain, c. Nausea, vomiting, d. Puncture <br>bleeding, e. Renal disorder, f. Inguinal hematoma, g. Liver dysfunction, h. Liver abscess, i. Intratumoral <br>hemorrhage<br>Intra-arterial contrast-enhanced ultrasound: a. Diarrhea, b. Headache, c. Proteinuria, d. Neutrocytopenia, <br>e. Rash, f. Dry mouth, g. Itching, h. Dyspnea, i. Low blood pressure
- Secondary Outcome Measures
Name Time Method